DOCSLIB.ORG

Potentially Harmful Drugs in the Elderly: Beers List and More

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Potentially Harmful Drugs in the Elderly: Beers List and More Detail-Document #230907 −This Detail-Document accompanies the related article published in− PHARMACIST’S LETTER / PRESCRIBER’S LETTER September 2007 ~ Volume 23 ~ Number 230907 Potentially Harmful Drugs in the Elderly: Beers List and More (B=Beers list drug; C=Canadian list drug) Drug Concern Alternative Treatment Analgesics Ketorolac (Toradol) GI bleeding.5 Mild pain: APAP, short-acting NSAID (e.g., (B); long-term use (C) ibuprofen) Meperidinea Not effective at (Demerol) (B); long- commonly used oral Moderate or severe pain: morphine, term use (C) doses; confusion, hydrocodone/APAP (Vicodin, etc), oxycodone falls, factures, (OxyContin, etc), oxycodone/APAP (Percocet, etc), dependency, fentanyl patch (Duragesic)19 withdrawal5,15 Pentazocine (Talwin) More CNS effects Topicals (neuropathic pain, arthritis): lidocaine (B); long-term use (C) (e.g., confusion, (Lidoderm), capsaicin (Zostrix, etc) hallucinations) than other opioids; ceiling to analgesic effect5 Propoxyphene (e.g., No better than Darvon, etc) (B) acetaminophen, but has narcotic AE5 Antidepressants Amitriptyline (Elavil) Anticholinergic AE, Tricyclic without active metabolites (Nortriptyline (B, C), doxepin sedation, urinary [Pamelor], desipramine [Norpramin])15 (Sinequan, etc) (B), retention or Trazodone (for insomnia)19 imipramine incontinence, SSRI15 (Tofranil)(C) constipation, Bupropion (Wellbutrin) (for cardiac patient)19 arrhythmias, falls5,15 Mirtazapine (Remeron) (for insomnia or anorexia)19 Neuropathic pain: topicals (lidocaine [Lidoderm], capsaicin [Zostrix, etc]) Bupropion May cause seizure5 Tricyclic without active metabolites (Nortriptyline (Wellbutrin), seizure [Pamelor], desipramine [Norpramin])15 disorder (B) Trazodone (for insomnia)19 SSRI15 Mirtazapine (Remeron) (for insomnia or anorexia)19 Fluoxetine (Prozac) Long half-life; SSRI with shorter half-life (e.g., escitalopram used daily (B) agitation, insomnia, [Lexapro], sertraline [Zoloft]) anorexia5 Tricyclic for Fall risk; urinary SSRI, with blood pressure monitoring15 depression in patient retention; worsening with postural glaucoma, heart hypotension, BPH, block15 glaucoma, heart block (C) More. Copyright © 2007 by Therapeutic Research Center Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249 www.pharmacistsletter.com ~ www.prescribersletter.com (Detail-Document #230907: Page 2 of 12) Drug Concern Alternative Treatment Antidepressants, cont. Tricyclic in patient Urinary retention or Antidepressant with little anticholinergic or alpha- with stress incontinence5 blocking effect (e.g., citalopram [Celexa]), bupropion incontinence or [Wellbutrin]) bladder outflow obstruction (B) SSRIs in patient with May cause or worsen Tricyclic without active metabolites (Nortriptyline SIADH (B) SIADH5 [Pamelor], desipramine [Norpramin])15 Trazodone (for insomnia)19 Bupropion (Wellbutrin) (for cardiac patient)19 Mirtazapine (Remeron) (for insomnia or weight loss)19 SSRI in patient on Enhanced SSRI side Avoid combination. If switching from MAOI to MAOI (C) effects15 another antidepressant, ensure a 14-day washout. If switching from another antidepressant to an MAOI, minimum washout is 2 weeks for drug without long half-life and 5 weeks for drug with long half-life (e.g., fluoxetine).30 Antihistamines Antihistamines, anticholinergic Anticholinergic AE, Cetirizine (Zyrtec), fexofenadine (Allegra), (B): urine retention, loratadine (Claritin), desloratadine Chlorpheniramine (Chlor- confusion, sedation5 (Clarinex), levocetirizine (Xyzal), low-dose Trimeton, etc), diphenhydramine19,26 Cyproheptadine (Periactin), Dexchlorpheniramine (Polaramine), Diphenhydramine (Benadryl, etc), Hydroxyzine (Vistaril, Atarax), Promethazine (Phenergan, etc) Antihypertensives Alpha-blockers Hypotension, dry mouth, Thiazide, ACE inhibitor, beta-blocker, (doxazosin [Cardura], incontinence5 calcium channel blocker22 prazosin [Minipress], terazosin [Hytrin])(B) Clonidine (Catapres) Orthostatic hypotension, CNS Thiazide, ACE inhibitor, beta-blocker, (B) AE5 calcium channel blocker22 Ethacrynic acid Hypotension; fluid, electrolyte Furosemide (Lasix), bumetanide (Bumex) (Edecrin) (B) imbalances5 Guanethidine (B) Orthostatic hypotension, Thiazide, ACE inhibitor, beta-blocker, depression5 calcium channel blocker22 Methyldopa Bradycardia; depression5 Thiazide, ACE inhibitor, beta-blocker, (Aldomet) (B) calcium channel blocker22 Nifedipine, short- Hypotension, constipation5 Another calcium channel blocker or long- acting (Procardia, acting nifedipine Adalat) (B) More. Copyright © 2007 by Therapeutic Research Center Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 Phone: 209-472-2240 ~ Fax: 209-472-2249 www.pharmacistsletter.com ~ www.prescribersletter.com (Detail-Document #230907: Page 3 of 12) Drug Concern Alternative Treatment Antihypertensives, cont. Reserpine >0.25mg Depression, impotence, Thiazide, ACE inhibitor, beta-blocker, (B, C) sedation, orthostatic calcium channel blocker22 hypotension, extrapyramidal effects5,15 Thiazide in patient May precipitate gout attack15 ACE inhibitor, beta-blocker, calcium with gout (C) channel blocker22 Antiplatelet Drugs Dipyridamole, short- Ineffective for stroke For stroke prevention: low-dose aspirin, clopidogrel acting (Persantine) prevention & (Plavix), aspirin/dipyridamole (Aggrenox)19 (B); for dementia or dementia; orthostatic stroke (C) hypotension5,15 Ticlopidine (Ticlid) Not more effective Low dose aspirin, clopidogrel (Plavix), (B) than aspirin, but more aspirin/dipyridamole (Aggrenox)19 toxic5 Antipsychotics Mesoridazine CNS AE, seizures, Risperidone (Risperdal)*, haloperidol (Haldol)26 (Serentil) (B), extrapyramidal effects5 Thioridazine *Atypicals associated with increased mortality when (Mellaril) (B) used to treat behavioral problems in elderly with dementia31 Chlorpromazine Fall risk15 Haloperidol, with blood pressure monitoring15 (Thorazine) in patient with history of postural hypotension (C) Clozapine (Clozaril) Lower seizure Risperidone (Risperdal)*, haloperidol (Haldol)26 in patient with threshold5 seizures (B) *Atypicals associated with increased mortality when used to treat behavioral problems in elderly with dementia31 Olanzapine (Zyprexa), Increased appetite, Risperidone (Risperdal)*, haloperidol (Haldol)26 obesity (B) weight gain *Atypicals associated with increased mortality when used to treat behavioral problems in elderly with dementia31 Thiothixene Lower seizure Risperidone (Risperdal)*, haloperidol (Haldol)26 (Navane), in patient threshold5 with seizure disorder *Atypicals associated with increased mortality when (B) used to treat behavioral problems in elderly with dementia31 More. Copyright © 2007 by Therapeutic Research Center Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 Phone: 209-472-2240 ~ Fax: 209-472-2249 www.pharmacistsletter.com ~ www.prescribersletter.com (Detail-Document #230907: Page 4 of 12) Drug Concern Alternative Treatment Anxiolytics Long-acting Dependence, For anxiety: shorter acting benzodiazepines benzodiazepines (B, depression, prolonged (appropriately dosed) (alprazolam C): sedation, confusion, [Xanax],lorazepam [Ativan], oxazepam [Serax]; clorazepate falls, fractures, buspirone (Buspar)15,19 (Tranxene, etc), respiratory depression chlordiazepoxide in COPD, For sleep: nondrug therapy (See our Detail- (Librium), diazepam incontinence5,15 Document #211015 [U.S.]/#210918 [Canada]); (Valium), quazepam temazepam (Restoril) 7.5 mg*, zolpidem (Ambien) (Doral) 5 mg*, Ambien CR 6.25 mg, zaleplon (Sonata) 5 mg*, ramelteon (Rozerem) 8 mg, eszopiclone (Lunesta) 1 mg* for difficulty falling asleep, 2 mg 15,19,32 for difficulty staying asleep *Initial dose Short-acting Falls5 For anxiety: shorter acting benzodiazepines benzodiazepines, (appropriately dosed) (alprazolam daily doses greater [Xanax],lorazepam [Ativan], oxazepam [Serax]; than (B): buspirone (Buspar)15,19 alprazolam (Xanax) 2 mg, lorazepam For sleep: nondrug therapy (See our Detail- (Ativan) 3 mg, Document #211015 [U.S.]/#210918 [Canada]); oxazepam (Serax) temazepam (Restoril) 7.5 mg*, zolpidem (Ambien) 60 mg 5 mg*, Ambien CR 6.25 mg, zaleplon (Sonata) Meprobamate Dependence, sedation5 5 mg*, ramelteon (Rozerem) 8 mg, eszopiclone (Miltown) (B) (Lunesta) 1 mg* for difficulty falling asleep, 2 mg for difficulty staying asleep15,19,32 *Initial dose Cardiac Drugs Amiodarone QT prolongation, Depends on type of arrhythmia; flecainide (Cordarone, torsades de pointes, (Tambocor), sotalol (Betapace), beta-blocker, Pacerone) (B) lack of efficacy in dofetilide (Tikosyn)27 elderly5 Beta-blockers in Worsening disease15 Alternate antihypertensive; nitrate or calcium patient with asthma, channel blocker15 COPD, or Raynaud’s disease (C)15 Calcium channel Worsening heart Diuretic, ACE inhibitor, appropriately titrated beta- blocker in patient failure; blocker15 with systolic heart constipation5,15 failure (C) or chronic constipation (B, C) Digoxin (Lanoxin) Toxicity due to Dose reduction, with monitoring19 doses >0.125 mg/d reduced renal except for atrial clearance5 arrhythmias (B) Disopyramide Negative inotrope; Depends on type of arrhythmia; for atrial fibrillation, (Norpace) (B, C) anticholinergic; digoxin, quinidine, procainamide, sotalol, sudden death5,15 flecainide15,27 More. Copyright © 2007 by Therapeutic Research Center Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 Phone: 209-472-2240 ~ Fax: 209-472-2249 www.pharmacistsletter.com ~ www.prescribersletter.com
Load more

Recommended publications
  • Angiotensin-Converting Enzyme Inhibitors Or Angiotensin II Receptor Blockers and the Risk of Developing Rheumatoid Arthritis in Antihypertensive Drug Users
    Jong, H.J.I. de, Vandebriel, R.J., Saldi, S.R.F., Dijk, L. van, Loveren, H. van, Cohen Tervaert, J.W., Klungel, O.H. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiology and Drug Safety: 2012, 21(8), 835-843 Postprint Version 1.0 Journal website http://dx.doi.org/10.1002/pds.3291 Pubmed link http://www.ncbi.nlm.nih.gov/pubmed/22674737 DOI 10.1002/pds.3291 This is a NIVEL certified Post Print, more info at http://www.nivel.eu Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users†‡ HILDA J. I. DE JONG1,2,3, ROB J. VANDEBRIEL1, SITI R. F. SALDI3, LISET VAN DIJK4, HENK VAN LOVEREN1,2, JAN WILLEM COHEN TERVAERT5, OLAF H. KLUNGEL3,* ABSTRACT Purpose: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are effective in the treatment of cardiovascular disease. Next to effects on hypertension and cardiac function, these drugs have anti-inflammatory and immunomodulating properties which may either facilitate or protect against the development of autoimmunity, potentially resulting in autoimmune diseases. Therefore, we determined in the current study the association between ACE inhibitor and ARB use and incident rheumatoid arthritis (RA). Methods: A matched case–control study was conducted among patients treated with antihypertensive drugs using the Netherlands Information Network of General Practice (LINH) database in 2001–2006. Cases were patients with a first-time diagnosis of RA. Each case was matched to five controls for age, sex, and index date, which was selected 1 year before the first diagnosis of RA.
    [Show full text]
  • Baclofen Overdose D
    Postgraduate Medical Journal (February 1980) 56, 108-109 Postgrad Med J: first published as 10.1136/pgmj.56.652.108 on 1 February 1980. Downloaded from Baclofen overdose D. J. LIPSCOMB* T. J. MEREDITHt M.B.. M.R.C.P. M.A., M.R.C.P. *Department of Medicine, Peterborough District Hospital, Peterborough PE3 6DA, and tPoisons Unit, Guy's Hospital, London SE] 9RT Summary Case report A 57-year-old woman suffering from multiple sclerosis A 51-year-old woman, who had suffered from took an estimated 1500 mg of baclofen. She became multiple sclerosis for 15 years, was prescribed baclo- deeply unconscious with generalized flaccid muscle fen 40 mg daily as part of her treatment for spastic paralysis and absent tendon reflexes. Toxicological paraplegia. One morning, she was found lying in analysis confirmed the presence of baclofen together bed unconscious and was admitted to hospital. with small amounts of paracetamol and glutethimide. Information given by her husband suggested that an Supportive therapy, including assisted ventilation for overdose of baclofen (consisting of 152 10-mg 3 days, led to complete recovery; anticonvulsant tablets) had been taken about 2 5 hr before being drugs were necessary for the treatment of grand mal found unconscious. On arrival in hospital 90 min fits. The clinical features and treatment of baclofen later, she was deeply unconscious and unresponsive overdose are discussed. to painful stimuli. Respiration was depressed and the cough reflex was absent. She was intubated without Introduction resistance and ventilated; gastric lavage was per-Protected by copyright. Baclofen (Lioresal, Ciba) is widely used in the formed but no tablets were returned in the lavage treatment of muscle spasticity.
    [Show full text]
  • The Pharmacology of Amiodarone and Digoxin As Antiarrhythmic Agents
    Part I Anaesthesia Refresher Course – 2017 University of Cape Town The Pharmacology of Amiodarone and Digoxin as Antiarrhythmic Agents Dr Adri Vorster UCT Department of Anaesthesia & Perioperative Medicine The heart contains pacemaker, conduction and contractile tissue. Cardiac arrhythmias are caused by either enhancement or depression of cardiac action potential generation by pacemaker cells, or by abnormal conduction of the action potential. The pharmacological treatment of arrhythmias aims to achieve restoration of a normal rhythm and rate. The resting membrane potential of myocytes is around -90 mV, with the inside of the membrane more negative than the outside. The main extracellular ions are Na+ and Cl−, with K+ the main intracellular ion. The cardiac action potential involves a change in voltage across the cell membrane of myocytes, caused by movement of charged ions across the membrane. This voltage change is triggered by pacemaker cells. The action potential is divided into 5 phases (figure 1). Phase 0: Rapid depolarisation Duration < 2ms Threshold potential must be reached (-70 mV) for propagation to occur Rapid positive charge achieved as a result of increased Na+ conductance through voltage-gated Na+ channels in the cell membrane Phase 1: Partial repolarisation Closure of Na+ channels K+ channels open and close, resulting in brief outflow of K+ and a more negative membrane potential Phase 2: Plateau Duration up to 150 ms Absolute refractory period – prevents further depolarisation and myocardial tetany Result of Ca++ influx
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • The Use of Intravenous Baclofen As Therapy for the Γ-Hydroxybutyric Acid Withdrawal Syndrome
    Research Article Remedy Open Access Published: 12 Jun, 2017 The Use of Intravenous Baclofen as Therapy for the γ-hydroxybutyric Acid Withdrawal Syndrome Marc Sabbe1*, Francis Desmet1 and Sabrina Dewinter2 1Department of Emergency Medicine, University Hospitals, Catholic University of Leuven, Belgium 2Department of Pharmacy, University Hospitals, Catholic University of Leuven, Belgium Abstract Introduction: In this case series with three patients, we introduced baclofen, a γ-aminobutyric acid type B(GABA-B) receptor agonist, for treatment of the γ-hydroxybutyric acid (GHB) withdrawal syndrome. Materials and Methods: Single center case series performed on three patientswith a GHB withdrawal syndrome. They initially received massive doses of benzodiazepines, without sufficient effect. Two patients also received an unsuccessful continuous dexmedetomidine drip. In all patients, intravenous baclofen was started, with an intravenous loading dose between 0.5 and 2 milligrams (mg) to achieve a therapeutic level. Thereafter a continuous intravenous dose between 0.5 and 1 mg per hour for 12 h was administered to maintain a steady state. After that, baclofen was substituted orally with a daily oral dose varying between 20 mg and 40 mg which could be downgraded and stopped over the next days. They all continued to receive a standard benzodiazepine regimen during the baclofen trial. Results and Discussion: Main outcome measurements were the degree of withdrawal symptoms and the need for benzodiazepines during baclofen treatment. In all patients, a significant reduction of the GHB withdrawal syndrome was noted. A standard daily regimen of baseline benzodiazepine dosing between 40 mg and 80 mg diazepam was sufficient. Adverse effects of baclofen use were absent.
    [Show full text]
  • Pharmacotherapeutic Considerations for Individuals with Down Syndrome Erik Hefti
    Harrisburg University of Science and Technology Digital Commons at Harrisburg University Harrisburg University Faculty Works 12-8-2016 Pharmacotherapeutic Considerations for Individuals with Down Syndrome Erik Hefti Follow this and additional works at: http://digitalcommons.harrisburgu.edu/faculty-works Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, and the Medicinal and Pharmaceutical Chemistry Commons R EVIEW O F T HERAPEUTICS Pharmacotherapeutic Considerations for Individuals with Down Syndrome Erik Hefti,* and Javier G. Blanco* Department of Pharmaceutical Sciences, The School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, New York Down syndrome (DS; trisomy 21) is the most common survivable disorder due to aneuploidy. Individ- uals with DS may experience multiple comorbid health problems including congenital heart defects, endocrine abnormalities, skin and dental problems, seizure disorders, leukemia, dementia, and obesity. These associated conditions may necessitate pharmacotherapeutic management with various drugs. The complex pathobiology of DS may alter drug disposition and drug response in some individuals. For example, reports have documented increased rates of adverse drug reactions in patients with DS treated for leukemia and dementia. Intellectual disability resulting from DS may impact adherence to medication regimens. In this review, we highlight literature focused on pharmacotherapy for individu- als with DS. We discuss reports of altered drug disposition or response in patients with DS and explore social factors that may impact medication adherence in the DS setting. Enhanced monitoring during drug therapy in individuals with DS is justified based on reports of altered drug disposition, drug response, and other characteristics present in this population.
    [Show full text]
  • Prescribing Trends of Antihistamines in the Outpatient Setting in Al-Kharj
    Prescribing Trends of Antihistamines in the Outpatient Setting in Al-Kharj Nehad J. Ahmed1*, Menshawy A. Menshawy2 1Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia, 2Department of Medicinal chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia Abstract Aim: This study aims to illustrate the prescribing trends of antihistamines in the outpatient setting in Al-Kharj. Materials and Methods: This is a retrospective study that included the evaluation of antihistamines in the outpatient setting in a public hospital in Al-Kharj. The data were collected from the pharmacy-based computer system. Results: The total number of prescriptions that included antihistamines was 799. Most of the prescribed ORIGINAL ARTICLE ARTICLE ORIGINAL antihistamines were first-generation sedating antihistamines (chlorphenamine and diphenhydramine) (66.33%). About 63.20% of the prescribed antihistamines included chlorpheniramine followed by cetirizine (19.27%) and loratadine (14.39%). Conclusion: Antihistamines were prescribed commonly in the outpatient setting mainly first-generation sedating antihistamines. It is recommended to increase the awareness of health- care providers about the efficacy and the side effects of antihistamines and to encourage them to use these agents wisely. Key words: Antihistamines, outpatient, prescribing, trends INTRODUCTION In addition, antihistamines have been classified as sedating antihistamines (first-generation antihistamines) and non- ntihistamines are used in the sedating antihistamines (second-generation antihistamines).[4] management of allergic conditions. Sedating antihistamines include chlorphenamine, clemastine, They are useful for treating the itching hydroxyzine, alimemazine, cyproheptadine, promethazine, A [1] and ketotifen.[4] Non-sedating antihistamines include that results from the release of histamine.
    [Show full text]
  • Tricyclic Antidepressant
    Princess Margaret Hospital for Children Emergency Department Guideline PAEDIATRIC ACUTE CARE GUIDELINE Poisoning – Tricyclic Antidepressant Scope (Staff): All Emergency Department Clinicians Scope (Area): Emergency Department This document should be read in conjunction with this DISCLAIMER http://kidshealthwa.com/about/disclaimer/ Poisoning – Tricyclic Antidepressant This guideline is a general approach to tricyclic antidepressant poisoning. For specific details please contact Poisons Information: 131126 or refer to the Toxicology Handbook. Agents: Amitriptyline Clomipramine Dothiepin Doxepin Imipramine Nortriptyline Trimipramine Background Tricyclic antidepressants (TCAs) act on a variety of receptors whose actions include: Noradrenaline reuptake inhibition Central and peripheral anticholinergic effect Fast sodium channel blockade in the myocardium Peripheral alpha1-adrenergic receptor blockade The life threatening effects of acute tricyclic antidepressant (TCA) overdose are: Rapid onset of coma Seizures Cardiac dysrhythmias Page 1 of 6 Emergency Department Guideline Poisoning – Tricyclic Antidepressant Hypotension and central and peripheral anticholinergic effects may also be seen Risk Assessment Most acute accidental paediatric exposures do not result in life threatening toxicity A 10kg child can develop life threatening poisoning with the ingestion of a single tablet (e.g. 150mg amitriptyline) Patients who ingest a large dose of TCA usually develop evidence of intoxication within 2-4 hours, and always within 6 hours If their is suspicion
    [Show full text]
  • Pediatric Pharmacotherapy
    Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 1, Number 10, October 1995 DIURETICS IN CHILDREN • Overview • Loop Diuretics • Thiazide Diuretics • Metolazone • Potassium Sparing Diuretics • Diuretic Dosages • Efficacy of Diuretics in Chronic Pulmonary Disease • Summary • References Pharmacology Literature Reviews • Ibuprofen Overdosage • Predicting Creatinine Clearance Formulary Update Diuretics are used for a wide variety of conditions in infancy and childhood, including the management of pulmonary diseases such as respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD)(1 -5). Both RDS and BPD are often associated with underlying pulmonary edema and clinical improvement has been documented with diuretic use.6 Diuretics also play a major role in the management of congestive heart failure (CHF), which is frequently the result of congenital heart disease (7). Other indications, include hypertension due to the presence of cardiac or renal dysfunction. Hypertension in children is often resistant to therapy, requiring the use of multidrug regimens for optimal blood pressure control (8). Control of fluid and electrolyte status in the pediatric population remains a therapeutic challenge due to the profound effects of age and development on renal function. Although diuretics have been used extensively in infants and children, few controlled studies have been conducted to define the pharmacokinetics and pharmacodynamics of diuretics in this population. Nonetheless, diuretic therapy has become an important part of the management of critically ill infants and children. This issue will review the mechanisms of action, monitoring parameters, and indications for use of diuretics in the pediatric population (1-5). Loop Diuretics Loop diuretics are the most potent of the available diuretics (4).
    [Show full text]
  • Medication: Amitriptyline 10 Mg
    Amitriptyline (Elavil) COMPLEX CHRONIC DISEASES PROGRAM Medication Handout Date: May 15, 2018 Medication: Amitriptyline 10 mg What is Amitriptyline? Amitriptyline belongs to a group of medications called tricyclic antidepressants (TCAs) that were first used to treat depression. It works by altering the levels of certain neuro- transmitters in the brain such as noradrenalin and serotonin. They have since been found to be effective for many different uses such as: pain, helping with sleep quality (but is not a sleeping pill), irritable bowel syndrome (with diarrhea), migraine prevention, and interstitial cystitis. Expected Benefit: Usually takes several weeks to notice a benefit You may not notice a benefit until you get to a dose of 25 mg Watch for possible side effects: This list of side effects is important for you to be aware of; however, it is also important to remember that not all side effects happen to all people. Many of these less serious side effects will improve over the first few days of taking the medications. If you have problems with these side effects talk with your doctor or pharmacist: Dry mouth – this is the most common side; the others are much less frequent Hangover effect – too sleepy in the morning Blurred vision Urinary retention, trouble with urination Tiredness, dizziness that is more than usual Diarrhea or constipation Stopping the medication: Do NOT stop taking this medication suddenly without asking your doctor – this medication is usually decreased slowly (at higher doses) before it is stopped completely How to use this medication: Take this medication with or without food Dosing Schedule: Start with 5 mg (½ tablet) 2 hrs before bed Increase dose according to table below Many patients can only tolerate 20 or 30 mg If you don’t have dry mouth or side effects, you can continue slowly increasing the dose to a maximum of 70 mg You can stay at a lower dose (stop increasing) if you get side effects (usually dry mouth).
    [Show full text]
  • Primary Structure and Functional Expression of a Cdna Encoding the Thiazide-Sensitive, Electroneutral Sodium-Chloride Cotransporter GERARDO GAMBA*, SAMUEL N
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 2749-2753, April 1993 Physiology Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride cotransporter GERARDO GAMBA*, SAMUEL N. SALTZBERG*t, MICHAEL LOMBARDI*, AKIHIKO MIYANOSHITA*, JONATHAN LYTTON*, MATTHIAS A. HEDIGER*, BARRY M. BRENNER*, AND STEVEN C. HEBERT*t§ *Laboratory of Molecular Physiology and Biophysics, Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Center for Study of Kidney Disease, Harvard Medical School, 75 Francis Street, Boston, MA 02115; and tMount Desert Island Biological Laboratory, Salsbury Cave, ME 04672 Communicated by Robert W. Berliner, December 17, 1992 ABSTRACT Electroneutral Na+:Cl- cotransport systems et al. (15) have identified a protein band of 185 kDa obtained are involved in a number of important physiological processes from membranes of rabbit renal cortex exposed to [3H]me- including salt absorption and secretion by epithelia and cell tolazone that may be a component of the thiazide-sensitive volume regulation. One group of Na+:Cl- cotransporters is Na+:Cl- cotransporter. specifically inhibited by the benzothiadiazine (thiazide) class of In this report we describe the sequence, functional and diuretic agents and can be distinguished from Na+:K+:2ClI pharmacological characterization, and tissue-specific expres- cotransporters based on a lack of K+ requirement and insen- sion of a cDNA clone (TSCil) encoding the electroneutral sitivity to sulfamoylbenzoic acid diuretics like bumetanide. We thiazide-sensitive Na+ :C1- cotransporter, isolated by a func- report here the isolation of a cDNA encoding a thiazide- tional expression strategy from the urinary bladder of the sensitive, electroneutral sodium-chloride cotransporter from euryhaline teleost P.
    [Show full text]
  • Cetirizine) – New Drug Approval
    Quzyttir™ (cetirizine) – New drug approval • On October 4, 2019, the FDA approved TerSera Therapeutics’ Quzyttir (cetirizine) injection, for the treatment of acute urticaria in adults and children 6 months of age and older. — Quzyttir is not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function. • Quzyttir is the first FDA approved intravenous (IV) formulation of cetirizine. Oral formulations of cetirizine are available generically as prescription as well as well over-the-counter (OTC) (eg, Zyrtec®). — Prescription oral cetirizine is approved for perennial allergic rhinitis and chronic urticaria. — Zyrtec and other OTC products are approved for use to temporarily relieve symptoms due to hay fever or other upper respiratory allergies: runny nose, sneezing, itchy and watery eyes, and itching of the nose or throat. • The efficacy of Quzyttir was established in a randomized, active-controlled, double-blind, single-dose study in 262 adult patients with acute urticaria. Patients were treated with Quzyttir or diphenhydramine injection. The primary efficacy endpoint was the change from baseline in patient-rated pruritus score assessed 2 hours post treatment. The study was non-inferiority design with the pre-specified non- inferiority margin of 0.50 for the difference between treatment groups. — The effectiveness of Quzyttir was demonstrated to be non-inferior to the effectiveness of diphenhydramine. The mean change from baseline in patient-rated pruritus score was -1.61 and -1.50 for Quzyttir and diphenhydramine, respectively (adjusted difference: 0.06; 95% CI: - 0.28, 0.40). • The efficacy of Quzyttir for the treatment of acute urticaria down to 6 months of age is based on extrapolation of the efficacy of Quzyttir in adults with acute urticaria and supported by pharmacokinetic data with oral cetirizine hydrochloride in patients 6 months to 17 years of age.
    [Show full text]